This site is intended for healthcare professionals outside the United States

CML 2021: How to manage treatment failure in CML

A patient-based approach

Meet the Expert sessions
Educational resources
Educational resources

Meet the Expert sessions

>

Session 1

Meet the Expert: Session 1

First-line treatment, diagnosis, family planning and intolerance

Recorded: Wednesday 13th October 2021

The first in the series of Meet the Expert sessions aims to increase confidence in diagnosis and first-line treatment options for CML, including alternative therapies in cases of intolerance and drug resistance and possible treatment plans for family planning.

Give us your feedback

Give us your feedback

Prof. Susanne Saußele, MD

III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, Mannheim, Germany

Prof. Susanne Saußele is Head of the CML Excellence Center and chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, both in Mannheim, Germany. She studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. In 2017, she was appointed as Professor of the University of Heidelberg.

Prof. Saußele is also a project leader in EUTOS (European Treatment and Outcome study of CML) and is a member of the E-MPN (European Network for MPN), ELN CML Working Party and Scientific Program Committee of EHA.

Faculty

Dr. Massimo Breccia, MD

Department of Translational and Precision Medicine, University of Rome, Rome, Italy

Dr. Massimo Breccia is a medical assistant at Sapienza University of Rome, Azienda Policlinico Umberto I, Head of DH unit. He has authored or co-authored over 450 papers in peer-reviewed journals with a focus on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes. He is a peer-reviewer for several journals, including Blood, The Lancet, The Lancet Hematology, Haematologica, British Journal of Haematology, and Cancer. Dr Breccia is also an editorial board member or associate editor of several journals including Frontiers in Oncology and Cancer.

He is a member of SIE, SIES, EHA and participates as PI and SI in several clinical trials for CML, AML, and MDS. He is co-chair of GIMEMA QoL Working Party and elected member of MPN GIMEMA Working Party.

Dr. Elisabetta Abruzzese, MD

Ospedale S.Eugenio, Università di Roma, Rome, Italy

Dr. Elisabetta Abruzzese is Director of the CML and Lymphoma Clinic at Ospedale S.Eugenio, ASL Roma2, Università di Roma, Tor Vergata, Rome, Italy. She is actively involved as Principal Investigator in multiple phase II and III studies of CML and lymphomas and was a co-founder for the Pregnancy and CML Treatment International Committee.Dr. Elisabetta Abruzzese is also a member of the Italian Society of Haematology, Italian Society of Experimental Haematology, American Society of Haematology, European LeukemiaNet and of the national board of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML.

Funding

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

Conference insights from
62nd ASH ANNUAL MEETING